Skip to main content

Table 1 Baseline characteristics of study participants (n = 33)

From: Physical activity measured using wearable activity tracking devices associated with gout flares

 

N (%) or mean (SD)

Age (years)

48.8 (14.9)

Sex

 Men

28 (84.9)

Race

 White*

27 (81.8)

 Black

5 (15.2)

 Other*

1 (3.0)

Education level

 Less than high school

1 (3.0)

 High school or G.E.D.

8 (24.2)

 Some college (junior college, technical degree, etc.)

13 (39.4)

 4-year college degree or higher

11 (33.3)

Age of first gout flare (years)

38.1 (18.6)

Duration of gout (years)

10.5 (8.2)

Number of flares prior 6 months

 1–3

16 (48.5)

 4–6

7 (21.2)

 > 6

10 (30.3)

Gout medication use

 Urate lowering therapy

29 (87.9)

 NSAID or colchicine

21 (63.6)

 Prednisone

12 (36.4)

Number of smartphone apps on cellphone

20.6 (17.2)

  1. NSAID non-steroidal anti-inflammatory; urate lowering therapy included allopurinol, febuxostat, or probenecid; not mutually exclusive to other gout medications
  2. *Two declared Hispanic ethnicity; missing data = 1